Research Signal – Source date 2021-12-23
A melanoma in the nasal lining and one on the skin share a name, but that does not mean they share the same biology or treatment prospects. In a 2021 review, researchers describe mucosal melanoma as a rare cancer arising in moist body linings, including the nose and mouth, digestive and urinary tracts, and female genital tract. They explain why a tumor’s location and exact genetic alteration can matter when interpreting treatment evidence.
The review was published on December 23, 2021, and its authors searched PubMed on November 1, 2021. It brings together sequencing studies, patient series, pooled treatment analyses, and early clinical trials. Those sources offer clues, but the groups studied differ, and the review itself does not test a new treatment or select one for an individual.
A melanoma with a different starting point
Mucosal melanomas account for about 1.5% of melanoma cases, according to the review. They most often begin in the head and neck, followed by the anus and rectum and the female genital tract. Because they arise in less visible places, they can go unnoticed early; the review also describes their tendency toward early spread and an overall poor prognosis.
Skin melanoma experience has not transferred cleanly to these tumors. Mucosal melanomas generally have fewer mutations than cutaneous melanomas, lack the ultraviolet-related mutation pattern common in many skin tumors, and show greater chromosomal instability. The review also describes a treatment gap: results with targeted drugs and immunotherapy have generally been less favorable than in cutaneous melanoma.
Even “mucosal melanoma” covers tumors with different molecular patterns. For example, the review reports that KIT alterations are more common in some genitourinary and anorectal melanomas, while head and neck tumors—especially those in the nasal passages—more often show NRAS or TERT-promoter mutations. A mutation frequency for one location therefore cannot automatically describe a tumor from another.
Sequencing can make the question more precise: which alteration is present, in which tumor site, and does the treatment evidence concern that same alteration? The gene name alone is not enough. For mucosal melanoma, the form of a mutation can change how useful a treatment clue is.
KIT findings depend on the alteration
KIT is a gene involved in cell signaling. Some mucosal melanomas carry KIT mutations, leading researchers to study drugs that inhibit the KIT protein. The review describes responses to KIT inhibitors—including imatinib, nilotinib, and dasatinib—among tumors with certain KIT mutations, especially those in exons 11 or 13. Exons are sections of a gene; identifying the affected section helps distinguish one mutation from another.
That specificity matters. In the reviewed evidence, KIT amplification (extra copies of the gene), a positive KIT stain in tumor tissue, and a mutation in exon 17 did not show comparable sensitivity to KIT inhibitors. A report that a tumor is “KIT-positive” therefore does not, by itself, capture the distinction the treatment evidence makes.
A pooled analysis of 19 studies that included mucosal and other melanoma types reported an objective response rate—the share of patients whose tumors shrank enough to meet response criteria—of 14% for mucosal melanoma across the KIT inhibitors studied. Nilotinib had the highest pooled response rate in that analysis, at 20%. These figures describe groups, and the review’s more specific point is that the exact KIT alteration matters when interpreting the possibility of response.
Other molecular findings point toward treatments still being studied. CDK4 amplification and loss of CDKN2A can disrupt controls on cell growth. The review describes CDK4/6 inhibitors such as palbociclib as a promising research direction, supported at that time by preclinical reasoning and case reports, with treatment under evaluation in clinical trials. It does not present this as an established treatment for mucosal melanoma.
Immune drugs show a response gap
Checkpoint inhibitors help the immune system attack cancer by blocking signals that can restrain immune cells. In the review’s pooled analysis of nivolumab studies, the objective response rate was 23.3% among patients with mucosal melanoma and 40.9% among those with cutaneous melanoma. Median progression-free survival—the time by which half the patients had disease progression or died—was 3.0 months for the mucosal group and 6.2 months for the cutaneous group.
Combining nivolumab with ipilimumab, another checkpoint inhibitor, was associated with higher reported response figures. In the same pooled analysis, objective response rates were 37.1% for mucosal and 60.4% for cutaneous melanoma; median progression-free survival was 5.9 and 11.7 months, respectively. The review also cites a five-year follow-up of 79 people with mucosal melanoma in CheckMate-067: response was reported in 43% of those receiving the combination and 7% receiving ipilimumab alone.
These results make combination treatment an encouraging possibility, but they do not establish a randomized head-to-head survival advantage for the combination across mucosal melanoma populations. The studies included patients with different starting characteristics, making direct comparisons difficult, and findings were not consistent across all studies. Combination therapy also came with more adverse events. The apparent increase in response must be read alongside that added burden and the limits of comparing unlike patient groups.
A strong early result still has a narrow frame
A phase IB trial tested toripalimab, an immune checkpoint inhibitor, with axitinib, a drug that limits new blood-vessel growth, in 29 Asian patients with metastatic mucosal melanoma who had not yet received treatment. The review reports an objective response rate of 48.3% and median progression-free survival of 7.5 months. The response rate is striking, but it belongs to this specific small study and patient group.
The result cannot tell us whether the same combination would perform similarly in a larger population, in people outside the Asian group studied, or compared with another treatment in a randomized trial. The review reports associations between better outcomes and two tumor features—how much PD-L1 protein the tumor made and how many mutations it carried—in this small study. Neither finding is a general treatment rule. The investigators’ result is a reason to test the combination further, not evidence that its response rate applies to every person with mucosal melanoma.
The review describes a field trying to connect tumor biology with treatment outcomes while facing a practical challenge: this cancer is rare, and studies often combine patients whose tumors differ by site and molecular features. It surveyed trials under way as of its 2021 search, including approaches in earlier disease and combinations for advanced or relapsed cancer. Those trial descriptions belong to the review’s historical account; they do not indicate present-day trial status.
Where this research could lead
For someone with a rare melanoma in the nasal lining, a future treatment discussion could draw on the tumor’s exact genetic alteration and reliable outcomes from people with mucosal melanoma, rather than relying on the shared label “melanoma” alone. The review offers a scientific bridge toward that possibility: some KIT mutations were linked with responses to KIT inhibitors, while immune-treatment results varied and differed from those for skin melanoma. More dependable evidence about who benefits—and what harms accompany treatment—could make those clues more useful in care.
The nearer milestone is a prospective study that reports response, survival, and adverse events for clearly defined mucosal melanoma groups, distinguishing tumor site and mutation where feasible. Such evidence could help show whether a molecular clue travels across sites or applies only to a narrower group. A future capability to match treatment more reliably depends on that kind of evidence accumulating; it was not yet established by the review.
Key Sources
- Primary source: Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive Review.
DOI or Journal Page · Review or Meta-Analysis · 2021-12-23
Keep exploring